A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Trial Profile

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs TTI 621 (Primary) ; Nivolumab; Rituximab
  • Indications Haematological malignancies; Hodgkin's disease; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Trillium Therapeutics
  • Most Recent Events

    • 12 Dec 2017 Results assessing the activity of TTI-621 in a cohort of patients with Diffuse Large B-Cell Lymphoma (n=14; As of June 1, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Nov 2017 According to a Trillium Therapeutics media release, data were presented at the Society for Immunotherapy of Cancer 32nd Annual Meeting.
    • 10 Nov 2017 According to a Trillium Therapeutics media release, data will be presented at the American Society of Hematology 59th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top